VERISILICON
15.5.2024 02:01:33 CEST | Business Wire | Press release
VeriSilicon (688521.SH) today announced that Actions Technology (688049.SH), a low-power AIoT fabless semiconductor company, has adopted VeriSilicon’s power-efficient and feature-rich 2.5D Graphics Processor Unit (GPU) IP in its highly integrated dual-mode Bluetooth smart watch SoC series, ATS3085S and ATS3089.
Featuring low power consumption and high frame rate, Actions Technology’s smart watch SoCs, ATS3085S and ATS3089 series, offer excellent graphics display performance with 2D+2.5D dual GPU hardware acceleration and support for JPEG hardware decoding. These SoCs, with their high level of integration, enable a single chip to drive display screens, run sports and health algorithms, perform Bluetooth calls, offer local audio decoding, and deliver Bluetooth audio transmission for True Wireless Stereo (TWS) headsets, providing mature dual-mode Bluetooth single-chip solutions supporting low-power Bluetooth 5.3 for end products such as smart bracelets and smart watches. Currently, smart watch products powered by ATS3085S and ATS3089 series SoCs have been mass-produced and launched in the market.
VeriSilicon’s 2.5D GPU IP is designed specifically for MCU and MPU applications that require hardware-accelerated User Interface (UI) display effects, and is capable of rendering vectors, scalars, and images in low-power modes, delivering high-performance, high-quality graphics processing capabilities and superior image output. It incorporates the company’s self-developed low-level, compact VGLite API driver to support the popular Light and Versatile Graphics Library (LVGL), enabling the creation of visually appealing UI across a wide range of hardware platforms and effectively reducing the size of their resources. The GCNanoUltraV 2.5D GPU also supports Scalable Vector Graphics (SVG) with VeriSilicon’s open-source tool SvgVGLiteRenderer, which parses SVG files and renders SVG content through the VGLite API. VeriSilicon’s 2.5D GPU IP has extended support for Baidu Maps and a variety of offline map formats, offering users a richer and more useful interactive experience.
Zhenyu Zhou, Chairman and CEO of Actions Technology, said, “VeriSilicon’s 2.5D GPU IP provides our smart watch SoCs with leading graphic rendering functions, enabling smoother UI interactions and appealing visual effects. The adoption of this technology significantly enhances the user experience of smart watches, meeting diverse needs of the global market, and thereby increasing our competitive advantages in the global wearable market.”
“As the resolutions and refresh rates of smart watch screens continue to improve, customers’ requirements for GPU performance are also increasing. VeriSilicon has effectively met the diverse needs of customers and drives the development of wearable applications through continuous technology innovation and actively building an ecosystem for key GPU applications,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “Our 2.5D GPU IP not only provides powerful graphics processing capabilities, but also enhances the performance-to-power ratio of Actions Technology’s smart watch SoCs to meet the needs of users who wear them for extended periods of time.”
About Actions Technology
Actions Technology (688049.SH) is a leading low-power AIoT fabless semiconductor company in China. We excel in providing high-quality and low-latency wireless audio experiences while prioritizing power efficiency. Our core expertise includes high-performance audio ADC/DAC, voice pre-processing, audio encoding/decoding, and audio post-processing technologies, enabling a superior audio signal chain. Additionally, we specialize in low-latency wireless connectivity with Bluetooth RF, baseband, and protocol stack technologies at the core. For more information about Actions® high-quality, low-latency platform, visit www.actionstech.com
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514705930/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom